News Conference News CRT 2025 Need for Rethink of Discharge Medications After LAA Closure? EMERGE L.A. McKeown March 12, 2025
News Conference News AHA 2023 Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina Michael O'Riordan November 11, 2023
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Conference News TCT 2021 Renal Denervation May Help Cut BP Meds, Sham-Controlled Trial Hints Todd Neale November 04, 2021
News Conference News TCT 2018 More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses Michael O'Riordan September 24, 2018
News Conference News ESC 2018 Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR Shelley Wood August 28, 2018
News Conference News ESC 2018 GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI Michael O'Riordan August 27, 2018
News Conference News ACC 2018 ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More Shelley Wood March 12, 2018
News Conference News ACC 2018 ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins Shelley Wood March 10, 2018
News Conference News AHA 2017 ‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18 Michael O'Riordan November 15, 2017
News Conference News ESC 2013 Length of DAPT, Reasons for Discontinuation Have Disparate Effects Yael L. Maxwell September 01, 2013